Effects of bisphosphonates on lipid metabolism

Basit Öğe Kaydı
dc.contributor.authorGuney, Engin
dc.contributor.authorKisakol, Gurcan
dc.contributor.authorOzgen, A. Gokhan
dc.contributor.authorYilmaz, Candeger
dc.contributor.authorKabalak, Taylan
dc.date.accessioned2020-03-26T17:26:44Z
dc.date.available2020-03-26T17:26:44Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOBJECTIVES: Bisphosphonates are widely used for the treatment of metabolic bone disorders and their effects on lipid metabolism have also been investigated. Some studies reported that bisphosphonates have beneficial effects on serum cholesterol levels. In this study we aimed to assess the effects of bisphosphonates on lipid levels in hyperlipidemic patients who received bisphosphonates because of osteoporosis. METHODS: 49 female patients (age: 54.2 +/- 7.2 years) with diagnosis of osteoporosis and hyperlipidemia were enrolled. Patients received alendronate 10 mg/day and they were followed up for 6 months. Pretreatment total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, apolipoprotein A1 and apolipoprotein B levels were measured and compared with post-treatment levels. RESULTS: Pretreatment and post-treatment levels of total cholesterol were 255.2 +/- 34.3; 233.02 +/- 37.0 mg/dL, triglyceride levels were 153.0 +/- 57.3; 129.1 +/- 54.4 mg/dL, and LDL levels were 170.7 +/- 30.5; 160.0 +/- 34.2 mg/dL, respectively. Reductions in total cholesterol, triglyceride and LDL-cholesterol levels were statistically significant; whereas differences in HDL-cholesterol, apolipoprotein-A1 and apolipoprotein-B levels were not significant. CONCLUSIONS: Data from our study suggest that alendronate therapy may have beneficial effects on lipid metabolism. Thus, when hyperlipidemia is detected in patients receiving bisphosphonates, it is considered reasonable to follow the patient for a while before initiating antihyperlipidemic agent to prevent unnecessary use of drugs.en_US
dc.identifier.endpage255en_US
dc.identifier.issn0172-780Xen_US
dc.identifier.issue2en_US
dc.identifier.pmid18404138en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage252en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22353
dc.identifier.volume29en_US
dc.identifier.wosWOS:000255490000010en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMAGHIRA & MAAS PUBLICATIONSen_US
dc.relation.ispartofNEUROENDOCRINOLOGY LETTERSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectbisphosphonatesen_US
dc.subjectlipiden_US
dc.subjectcholesterolen_US
dc.subjectosteoporosisen_US
dc.titleEffects of bisphosphonates on lipid metabolismen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu